newsfilter
← Latest News
ACCESS Newswire·

Protagonist Announces Nomination of PN-477, an Oral and Injectable GLP-1R, GIPR, and GCGR Triple Agonist Peptide Development Candidate for Obesity

A novel oral peptide PN-477o with once-daily dosing, high potency and activation of glucagon-like peptide-1 , glucose-dependent insulinotropic peptide , and glucagon receptorsCompany will also develop a